Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

NCT03655444 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Provider of drug decided to discontinue study.

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Abemaciclib
DRUG: Nivolumab
PROCEDURE: Tumor biopsy
PROCEDURE: Peripheral blood
OTHER: EORTC QLQ-30

Sponsor

Washington University School of Medicine

Collaborators

[object Object]